Table 2 Baseline characteristics of the randomised clinical trials evaluating the efficacy of topical treatment for vernal keratoconjunctivitis.

Trial	Country	Intervention	No of patients at baseline	Final no of patients	Outcome measure	Quality score*
Easty et al10	UK	Sodium cromoglycate 1% vs placebo	22	22	Signs, symptoms	9
Tabbara and Arafat11	Lebanon	Sodium cromoglycate 2% vs placebo	14	14	Signs	9
Foster and Duncan12	USA	Sodium cromoglycate 4% vs placebo	11	11	Signs, symptoms	9
Foster16	USA	Sodium cromoglycate 4% vs placebo	72	65	Signs, symptoms	9
Secchi et al17	Italy	Ciclosporin 2% vs placebo	11	9	Signs, symptoms	9
Bleik and Tabbara18	Saudi Arabia	Ciclosporin 2% vs placebo	20	20	Signs, symptoms	9
Centofanti et al25	Italy	Mipragoside 0.5% vs placebo	24	20	Signs, symptoms	9
Sharma et al28	India	Ketorolac 0.5% vs placebo	21	21	Signs, symptoms	9
Akpek et al31	Turkey	Mitomycin‐C 0.01% vs placebo	26	26	Signs, symptoms	8
Pucci et al34	Italy	Ciclosporin 2% vs placebo	24	24	Signs, symptoms	9

*Delphi List (0–9).